Related Experiment Video
Updated: Jun 1, 2026

The Stroke Preclinical Assessment Network Multi-Laboratory Model of Thromboembolic Stroke with Thrombolysis: TE-MCAo
Published on: December 19, 2025
Post-operative deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious risks. Prophylactic medications significantly reduce these risks and related deaths without increasing bleeding complications.
Area of Science:
- Medical research
- Clinical trials
- Pharmacology
Context:
- Deep vein thrombosis (DVT) and pulmonary embolism (PE) are significant post-operative complications.
- Risk factors include patient age, general health, operation duration, and surgical procedure type.
- Effective thromboprophylaxis is crucial for patient safety.
Purpose:
- To review the outcomes of controlled trials on surgical thromboprophylaxis.
- To evaluate the efficacy of various prophylactic medications.
- To provide evidence-based recommendations for preventing post-operative venous thromboembolism.
Summary:
- Prophylactic therapy with unfractionated heparin, low molecular weight heparin, or two-step warfarin is effective.
- These treatments can reduce PE-related post-operative deaths by 70%.
- DVT incidence is reduced by 50-80% with no significant increase in serious bleeding.
Impact:
- Demonstrates substantial risk reduction for DVT and PE post-surgery.
- Highlights the safety profile of prophylactic anticoagulants.
- Informs clinical practice guidelines for surgical thromboprophylaxis.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
